Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 21, 2016, Pages E2993-E3001

  Fischer, Natalie ^a,d   Sechet, Emmanuel ^a   Friedman, Robin ^a   Amiot, Aurélien ^b   Sobhani, Iradj ^b   Nigro, Giulia ^a   Sansonetti, Philippe J ^a,c   Sperandio, Brice ^a  

^a INSTITUT PASTEUR   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Chr de Microbiologie et Maladies Infectieuses   (France)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylation; Antimicrobial peptides; Colonic mucosa|epithelial cells; Epigenetic

Indexed keywords

BETA DEFENSIN 2; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; POLYPEPTIDE ANTIBIOTIC AGENT; TRICHOSTATIN A; BETA DEFENSIN; DEFB4A PROTEIN, HUMAN; EP300 PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; IL8 PROTEIN, HUMAN;

ARTICLE; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; EPIGENETICS; EPITHELIUM CELL; ESCHERICHIA COLI K 12; GENE CONTROL; HUMAN; HUMAN CELL; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; CACO-2 CELL LINE; DRUG EFFECTS; GENETIC EPIGENESIS; IMMUNOLOGY;

BETA-DEFENSINS; CACO-2 CELLS; E1A-ASSOCIATED P300 PROTEIN; EPIGENESIS, GENETIC; ESCHERICHIA COLI K12; HISTONE DEACETYLASE INHIBITORS; HUMANS; INTERLEUKIN-8; NF-KAPPA B;

EID: 84969766631     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1605997113     Document Type: Article

References (42)

1. Nightingale KP, O'Neill LP, Turner BM (2006) Histone modifications: Signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev 16(2):125-136.
2. Kouzarides T (2007) SnapShot: Histone-modifying enzymes. Cell 128(4):802.
3. Arbibe L, et al. (2007) An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat Immunol 8(1):47-56.
4. Eskandarian HA, et al. (2013) A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection. Science 341(6145):1238858.
5. Lehrmann H, Pritchard LL, Harel-Bellan A (2002) Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86:41-65.
6. Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: Discovery and development as anticancer agents. Expert Opin Investig Drugs 14(12):1497-1511.
7. Codd R, Braich N, Liu J, Soe CZ, Pakchung AAH (2009) Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilide hydroxamic acid and trichostatin A. Int J Biochem Cell Biol 41(4):736-739.
8. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1):38-51.
9. Baldwin AS, Jr (1996) The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 14:649-683.
10. Kouzarides T (2000) Acetylation: A regulatory modification to rival phosphorylation? EMBO J 19(6):1176-1179.
11. Ghizzoni M, Haisma HJ, Maarsingh H, Dekker FJ (2011) Histone acetyltransferases are crucial regulators in NF-κB mediated inflammation. Drug Discov Today 16(11-12):504-511.
12. Huang B, Yang X-D, Lamb A, Chen L-F (2010) Posttranslational modifications of NF-kappaB: Another layer of regulation for NF-kappaB signaling pathway. Cell Signal 22(9):1282-1290.
13. Kiernan R, et al. (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278(4):2758-2766.
14. Chen L-F, Mu Y, Greene WC (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21(23):6539-6548.
15. Weake VM, Workman JL (2010) Inducible gene expression: Diverse regulatory mechanisms. Nat Rev Genet 11(6):426-437.
16. Chantret I, et al. (1994) Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line Caco-2: Evidence for glucose-dependent negative regulation. J Cell Sci 107(Pt 1):213-225.
17. Schauber J, et al. (2003) Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: Relevance of signalling pathways. Gut 52(5):735-741.
18. Saccani S, Pantano S, Natoli G (2002) p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 3(1):69-75.
19. Anest V, et al. (2003) A nucleosomal function for IkappaB kinase-alpha in NF-kappaBdependent gene expression. Nature 423(6940):659-663.
20. Yamamoto Y, Verma UN, Prajapati S, Kwak Y-T, Gaynor RB (2003) Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 423(6940):655-659.
21. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18(18):2195-2224.
22. Wehkamp J, et al. (2004) NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: A novel effect of a probiotic bacterium. Infect Immun 72(10):5750-5758.
23. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M (2002) Multiple control of interleukin-8 gene expression. J Leukoc Biol 72(5):847-855.
24. Burke JR, et al. (2003) BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 278(3):1450-1456.
25. Yang X-D, Tajkhorshid E, Chen L-F (2010) Functional interplay between acetylation and methylation of the RelA subunit of NF-kappaB. Mol Cell Biol 30(9): 2170-2180.
26. Bowers EM, et al. (2010) Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor. Chem Biol 17(5):471-482.
27. Sato T, et al. (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141(5): 1762-1772.
28. Leoni F, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99(5):2995-3000.
29. Salzman NH, Underwood MA, Bevins CL (2007) Paneth cells, defensins, and the commensal microbiota: A hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol 19(2):70-83.
30. Rescigno M, Borrow P (2001) The host-pathogen interaction: New themes from dendritic cell biology. Cell 106(3):267-270.
31. Tato CM, Hunter CA (2002) Host-pathogen interactions: Subversion and utilization of the NF-kappa B pathway during infection. Infect Immun 70(7):3311-3317.
32. Huang Q, et al. (2001) The plasticity of dendritic cell responses to pathogens and their components. Science 294(5543):870-875.
33. Foster SL, Hargreaves DC, Medzhitov R (2007) Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447(7147):972-978.
34. Clayton AL, Mahadevan LC (2003) MAP kinase-mediated phosphoacetylation of histone H3 and inducible gene regulation. FEBS Lett 546(1):51-58.
35. Cheung P, Allis CD, Sassone-Corsi P (2000) Signaling to chromatin through histone modifications. Cell 103(2):263-271.
36. Duan J, et al. (2007) Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 6(1):37-50.
37. Katsura T, et al. (2009) The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther 16(3):237-245.
38. Gerritsen ME, et al. (1997) CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 94(7):2927-2932.
39. Sheppard KA, et al. (1999) Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol 19(9):6367-6378.
40. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769-784.
41. Ververis K, Karagiannis TC (2011) Potential non-oncological applications of histone deacetylase inhibitors. Am J Transl Res 3(5):454-467.
42. Raqib R, et al. (2006) Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci USA 103(24):9178-9183.